Unnamed: 0,title,date,stock,sentiment
650566.0,"Baird Maintains Neutral on Icon, Lowers Price Target to $145",2020-04-24 12:26:00-04:00,ICLR,negative
650567.0,"Deutsche Bank Maintains Hold on Icon, Lowers Price Target to $135",2020-04-24 10:53:00-04:00,ICLR,negative
650568.0,"Credit Suisse Maintains Outperform on Icon, Lowers Price Target to $181",2020-04-23 08:22:00-04:00,ICLR,positive
650569.0,"Barclays Maintains Overweight on Icon, Raises Price Target to $180",2020-04-23 07:22:00-04:00,ICLR,negative
650570.0,CORRECTION: ICON Q1 Adj. EPS $1.70 Beats $1.68 Estimate,2020-04-22 16:39:00-04:00,ICLR,neutral
650571.0,ICON Withdraws FY20 Guidance,2020-04-22 16:18:00-04:00,ICLR,neutral
650572.0,"Icon Q1 Adj. EPS $1.70 Beats $1.680 Estimate, Sales $715.100M Beat $707.220M Estimate",2020-04-22 16:17:00-04:00,ICLR,neutral
650573.0,"Earnings Scheduled For April 22, 2020",2020-04-22 04:07:00-04:00,ICLR,neutral
650574.0,"Baird Downgrades Icon to Neutral, Announces $151 Price Target",2020-04-20 06:18:00-04:00,ICLR,neutral
650575.0,"Citigroup Maintains Neutral on Icon, Lowers Price Target to $160",2020-04-09 08:48:00-04:00,ICLR,negative
650576.0,"Wells Fargo Maintains Equal-Weight on Icon, Lowers Price Target to $140",2020-03-30 12:13:00-04:00,ICLR,positive
650577.0,"Benzinga's Top Upgrades, Downgrades For March 26, 2020",2020-03-26 10:01:00-04:00,ICLR,positive
650578.0,"Barclays Upgrades Icon to Overweight, Lowers Price Target to $170",2020-03-26 06:51:00-04:00,ICLR,negative
650579.0,"Jefferies Maintains Buy on Icon, Lowers Price Target to $146",2020-03-23 09:22:00-04:00,ICLR,negative
650580.0,"SunTrust Robinson Humphrey Maintains Hold on Icon, Lowers Price Target to $131",2020-03-17 12:10:00-04:00,ICLR,negative
650581.0,"Benzinga's Top Upgrades, Downgrades For March 2, 2020",2020-03-02 09:40:00-05:00,ICLR,positive
650582.0,"Deutsche Bank Initiates Coverage On Icon with Hold Rating, Announces $169 Price Target",2020-03-02 07:23:00-05:00,ICLR,neutral
650583.0,"UBS Maintains Neutral on Icon, Raises Price Target to $182",2020-02-21 08:31:00-05:00,ICLR,neutral
650584.0,"Barclays Maintains Equal-Weight on Icon, Raises Price Target to $182",2020-02-20 11:52:00-05:00,ICLR,neutral
650585.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-20 10:26:00-05:00,ICLR,neutral
650586.0,"Mizuho Reiterates Buy on Icon, Raises Price Target to $194",2020-02-20 07:43:00-05:00,ICLR,neutral
650587.0,"Icon Q4 EPS $1.83, Inline, Sales $725.409M Miss $733.82M Estimate",2020-02-19 16:56:00-05:00,ICLR,negative
650588.0,"Earnings Scheduled For February 19, 2020",2020-02-19 04:01:00-05:00,ICLR,neutral
650589.0,"Benzinga's Top Upgrades, Downgrades For January 27, 2020",2020-01-27 09:40:00-05:00,ICLR,positive
650590.0,"SunTrust Robinson Humphrey Downgrades Icon to Hold, Raises Price Target to $182",2020-01-27 07:37:00-05:00,ICLR,neutral
650591.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,ICLR,neutral
650592.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,ICLR,neutral
650593.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,ICLR,neutral
650594.0,"ICON Sees FY20 EPS $7.55-$7.85 vs $7.71 Est., Sales $2.972B-$3.092B vs $3.03B Est.",2020-01-14 06:05:00-05:00,ICLR,neutral
650595.0,"Benzinga's Top Upgrades, Downgrades For January 8, 2020",2020-01-08 10:56:00-05:00,ICLR,positive
650596.0,"Wells Fargo Initiates Coverage On Icon with Equal-Weight Rating, Announces $180 Price Target",2020-01-08 09:11:00-05:00,ICLR,positive
650597.0,"Citigroup Initiates Coverage On Icon with Neutral Rating, Announces $185 Price Target",2020-01-07 07:13:00-05:00,ICLR,neutral
650598.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,ICLR,neutral
650599.0,Stocks That Hit 52-Week Highs On Friday,2019-12-20 11:59:00-05:00,ICLR,neutral
650600.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-19 10:29:00-05:00,ICLR,neutral
650601.0,ICON Raises FY19 Adj. EPS Guidance From $6.75-$6.95 To $6.81-$6.95 vs $6.88 Est.; Narrows Sales Guidance From $2.76B-$2.84B To $2.79B-$2.83B vs $2.81B Est.,2019-10-23 16:22:00-04:00,ICLR,neutral
650602.0,"Icon Q3 Adj. EPS $1.74, Inline, Sales $710.4M Beat $709.52M Estimate",2019-10-23 16:20:00-04:00,ICLR,neutral
650603.0,"UBS Maintains Neutral on Icon, Lowers Price Target to $158",2019-10-18 08:05:00-04:00,ICLR,negative
650604.0,"Benzinga's Top Upgrades, Downgrades For September 23, 2019",2019-09-23 12:47:00-04:00,ICLR,positive
650605.0,KeyBanc Downgrades Icon to Sector Weight,2019-09-23 05:50:00-04:00,ICLR,neutral
650606.0,"KeyBanc Maintains Overweight on Icon, Raises Price Target to $165",2019-08-08 06:09:00-04:00,ICLR,negative
650607.0,"Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.",2019-08-06 13:54:00-04:00,ICLR,positive
650608.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,ICLR,neutral
650609.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2019",2019-07-26 10:12:00-04:00,ICLR,positive
650610.0,10 Biggest Price Target Changes For Friday,2019-07-26 09:37:00-04:00,ICLR,neutral
650611.0,"UBS Upgrades Icon to Neutral, Raises Price Target to $171",2019-07-26 08:19:00-04:00,ICLR,neutral
650612.0,"Mizuho Maintains Buy on Icon, Raises Price Target to $170",2019-07-25 08:10:00-04:00,ICLR,neutral
650613.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,ICLR,neutral
650614.0,"Icon Q2 EPS $1.69 Beats $1.68 Estimate, Sales $695.1M Beat $693.71M Estimate",2019-07-24 17:33:00-04:00,ICLR,neutral
650615.0,"ICON Reports Purchase Of MeDiNova Research, No Terms Disclosed",2019-05-23 09:08:00-04:00,ICLR,negative
650616.0,"Icon Q1 EPS $1.63 Beats $1.6 Estimate, Sales $675M Beat $668.3M Estimate",2019-05-01 17:10:00-04:00,ICLR,neutral
650617.0,10 Biggest Price Target Changes For Thursday,2019-02-21 09:55:00-05:00,ICLR,neutral
650618.0,"Barclays Maintains Equal-Weight on Icon, Raises Price Target to $140",2019-02-21 07:58:00-05:00,ICLR,neutral
650619.0,"Icon Reaffirms FY19 Guidance; Sees EPS $6.69-$6.89 vs $6.81 Est., Sales $2.74B-$2.84B vs $2.78B Est.",2019-02-20 16:29:00-05:00,ICLR,neutral
650620.0,"Icon Q4 EPS $1.63 Beats $1.60 Estimate, Sales $679M Beat $675.88M Estimate",2019-02-20 16:27:00-05:00,ICLR,neutral
650621.0,"Earnings Scheduled For February 20, 2019",2019-02-20 04:04:00-05:00,ICLR,neutral
650622.0,10 Biggest Price Target Changes For Friday,2019-01-25 09:40:00-05:00,ICLR,neutral
650623.0,"Benzinga's Top Upgrades, Downgrades For January 25, 2019",2019-01-25 09:10:00-05:00,ICLR,positive
650624.0,"Mizuho Upgrades Icon to Buy, Raises Price Target to $150",2019-01-25 07:01:00-05:00,ICLR,neutral
650625.0,ICON Intends To Repurchase Up To 1 Million Shares During 2019,2019-01-08 06:13:00-05:00,ICLR,positive
650626.0,"ICON Reaffirms FY18 Guidance; Sees EPS $5.98-$6.12 vs $6.08 Est., Sales $2.56B-$2.64B vs $2.59B Est.",2019-01-08 06:12:00-05:00,ICLR,neutral
650627.0,"ICON Sees FY19 EPS $6.69-$6.89 vs $6.90 Est., Sales $2.38B-$3.84B vs $2.79B Est.",2019-01-08 06:11:00-05:00,ICLR,neutral
650628.0,"Benzinga's Top Upgrades, Downgrades For October 26, 2018",2018-10-26 09:22:00-04:00,ICLR,positive
650629.0,Evercore ISI Group Upgrades Icon to Outperform,2018-10-26 07:17:00-04:00,ICLR,neutral
650630.0,"ICON Q3 Adj. EPS $1.55 Beats $1.54 Estimate, Sales $655M Beat $654.4M Estimate",2018-10-24 17:03:00-04:00,ICLR,neutral
650631.0,"Earnings Scheduled For October 24, 2018",2018-10-24 04:05:00-04:00,ICLR,neutral
650632.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,ICLR,neutral
650633.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,ICLR,neutral
650634.0,"KeyBanc Maintains Overweight on Icon, Raises Price Target to $157",2018-09-11 06:35:00-04:00,ICLR,negative
650635.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,ICLR,neutral
650636.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,ICLR,neutral
650637.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,ICLR,neutral
650638.0,ICON Reports Confirmation Of Co-Founder Ronan Lambe To Retire,2018-07-27 06:07:00-04:00,ICLR,neutral
650639.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,ICLR,neutral
650640.0,"Icon Q2 EPS $1.54 Beats $1.48 Estimate, Sales $641.6M Beat $632.69M Estimate",2018-07-25 16:42:00-04:00,ICLR,neutral
650641.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,ICLR,neutral
650642.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,ICLR,neutral
650643.0,ICON Reports Collaboration With Practice Fusion 'to leverage active patient data in support of health research',2018-06-27 07:07:00-04:00,ICLR,positive
650644.0,"Credit Suisse Maintains Outperform on Icon, Raises Price Target to $144",2018-06-19 09:05:00-04:00,ICLR,positive
650645.0,"KeyBanc Maintains Overweight on Icon, Raises Price Target to $152",2018-06-18 13:07:00-04:00,ICLR,negative
650646.0,Icon Increases FY18 EPS Guidance $0.02 To $5.91-$6.11,2018-05-02 16:30:00-04:00,ICLR,neutral
650647.0,"Icon Q1 EPS $1.44 Beats $1.42 Estimate, Sales $620.1M Miss $624.52M Estimate",2018-05-02 16:29:00-04:00,ICLR,negative
650648.0,ICON Announces it Will Sell the Intel Pharma Analytics Platform for Clinical Trials,2018-04-17 07:29:00-04:00,ICLR,neutral
650649.0,Evercore ISI Group Downgrades Icon to In-Line,2018-04-03 07:52:00-04:00,ICLR,neutral
650650.0,"ICON Updates FY18 Sales Guidance To Reflect New Sales Recognition Standard: $2.52B-$2.64B, Reaffirms EPS Outlook Of $5.89-$6.09",2018-02-15 06:13:00-05:00,ICLR,neutral
650651.0,"ICON Reports Q4 EPS $1.43 vs $1.42 Est., Sales $455M vs $454.6M Est.",2018-02-15 06:12:00-05:00,ICLR,neutral
650652.0,"Earnings Scheduled For February 15, 2018",2018-02-15 04:12:00-05:00,ICLR,neutral
650653.0,"Evercore ISI Group Initiates Coverage On Icon with Outperform Rating, Announces $126.00 Price Target",2018-01-19 08:21:00-05:00,ICLR,neutral
650654.0,"ICON Sees FY18 EPS $5.89-$6.09 vs $5.96 Est., Sales $1.87-$1.93B vs $1.89B Est.",2018-01-09 06:06:00-05:00,ICLR,neutral
650655.0,ICON Raises FY17 EPS Outlook From $5.18-$5.38 To $5.30-$5.40 vs $5.33 Est.; Sales Guidance Reaffirmed At $1.74B-$1.77B vs $1.75B Est.,2017-10-26 06:07:00-04:00,ICLR,neutral
650656.0,"ICON plc Reports Q3 EPS $1.35 vs $1.32 Est., Sales $440M vs $436.4M Est.",2017-10-26 06:06:00-04:00,ICLR,neutral
650657.0,"Bank of America Earlier Initiated Coverage On ICON plc - Ordinary Shares with Buy Rating, Announced $128.00 Price Target",2017-09-11 10:11:00-04:00,ICLR,positive
650658.0,SunTrust Robinson Humphrey Upgrades ICON plc - Ordinary Shares to Buy,2017-07-31 07:24:00-04:00,ICLR,positive
650659.0,"Wall Street's M&A Chatter From July 27: Nordstrom, Mitel-ShoreTel, ICON-Mapi Group, BMC Software-CA",2017-07-28 07:11:00-04:00,ICLR,neutral
650660.0,"ICON Sees FY17 EPS $5.18-$5.38 vs $5.17 Est., Sales $1.74-$1.77B vs $1.73B Est.",2017-07-27 07:26:00-04:00,ICLR,neutral
650661.0,"ICON Reports Q2 EPS $1.31 vs $1.30 Est., Sales $431M vs $430M Est.",2017-07-27 07:25:00-04:00,ICLR,neutral
650662.0,"ICON Reports Purchase Of Mapi Group, No Terms Disclosed",2017-07-27 06:16:00-04:00,ICLR,negative
650663.0,ICON Shares Added To Goldman's 'Conviction Buy' List,2017-07-07 09:21:00-04:00,ICLR,positive
650664.0,ICON Shares Indicated Up 0.6% Premarket Following Goldman Adding Stock To Its 'Conviction Buy' List,2017-07-07 08:21:00-04:00,ICLR,positive
650665.0,"Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research",2017-06-29 14:46:00-04:00,ICLR,neutral
650666.0,"Benzinga's Top Upgrades, Downgrades For June 29, 2017",2017-06-29 09:33:00-04:00,ICLR,positive
650667.0,The Market In 5 Minutes,2017-06-29 09:10:00-04:00,ICLR,neutral
650668.0,Jefferies Upgrades ICON plc - Ordinary Shares to Buy,2017-06-29 07:15:00-04:00,ICLR,positive
650669.0,"UPDATE: ICON Raises FY17 EPS Outlook from $5-$5.20 to $5.06-$5.26 vs $5.10 Est., Sales Outlook Affirmed",2017-04-27 06:30:00-04:00,ICLR,neutral
650670.0,"ICON Reports Q1 EPS $1.29 vs $1.27 Est., Sales $432M, Inline; Raises Outlook",2017-04-27 06:29:00-04:00,ICLR,neutral
650671.0,"ICON Q4 EPS $1.33 vs $1.26 Est, Revenue $435.1M vs $440.8M Est",2017-02-16 06:15:00-05:00,ICLR,neutral
650672.0,"ICON Sees FY17 EPS $5-$5.20 vs $5.13 Est., Sales $1.7B-$1.75B vs $1.75B Est.",2017-01-09 16:16:00-05:00,ICLR,neutral
650673.0,7 Biggest Price Target Changes For Friday,2016-12-16 09:11:00-05:00,ICLR,neutral
650674.0,"SunTrust Robinson Humphrey Downgrades ICON plc - Ordinary Shares to Hold, Lowers Target to $80.00",2016-12-16 07:58:00-05:00,ICLR,positive
650675.0,"Goldman Sachs Upgrades ICON plc - Ordinary Shares to Buy, Raises Target to $90.00",2016-12-16 06:06:00-05:00,ICLR,positive
650676.0,Jefferies London Healthcare Conference Taking Place Today,2016-11-16 10:52:00-05:00,ICLR,neutral
650677.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-11-02 06:49:00-04:00,ICLR,neutral
650678.0,18 Biggest Mid-Day Gainers For Thursday,2016-10-20 12:46:00-04:00,ICLR,neutral
650679.0,Stocks  Hitting 52-Week Highs,2016-10-20 10:22:00-04:00,ICLR,neutral
650680.0,"9 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-10-20 06:41:00-04:00,ICLR,neutral
650681.0,Icon Reports Q3 EPS $1.19 vs $1.18 Est; Revenue $420.201M vs $420.1M Est,2016-10-20 04:38:00-04:00,ICLR,neutral
650683.0,Benzinga's Top Upgrades,2016-10-14 09:28:00-04:00,ICLR,positive
650684.0,Evercore ISI Group Upgrades ICON plc - Ordinary Shares to Buy,2016-10-14 07:13:00-04:00,ICLR,positive
650685.0,"ICON Q2 EPS $1.14 vs $1.14 est, Revenue $411M vs $410M est",2016-07-26 06:13:00-04:00,ICLR,neutral
650686.0,"ICON to Buy Clinical Research Management, No Terms Disclosed",2016-06-30 08:01:00-04:00,ICLR,negative
650687.0,"ICON May Miss Revenue Guidance, But Baird Still Bullish",2016-06-24 13:49:00-04:00,ICLR,negative
650688.0,Vol Spike in Icon,2016-06-22 11:33:00-04:00,ICLR,neutral
650689.0,"Credit Suisse Initiates Coverage on Icon at Outperform, Announces $80.00 PT",2016-06-21 04:18:00-04:00,ICLR,positive
650690.0,A Peek Into The Markets: U.S. Stock Futures Slide Ahead Of Consumer Sentiment Report,2016-06-10 07:54:00-04:00,ICLR,neutral
650691.0,ICON Reveals Service Deal With Pfizer,2016-06-10 07:17:00-04:00,ICLR,neutral
650692.0,"ICON Reports Service Deal with Pfizer, No Terms Disclosed",2016-06-10 06:02:00-04:00,ICLR,negative
650693.0,Avondale Worried About ICON PLC's Revenue Concentration,2016-06-08 17:59:00-04:00,ICLR,negative
650694.0,"Avondale Partners Downgrades Icon to Market Underperform, Lowers PT to $59.00",2016-06-08 16:33:00-04:00,ICLR,negative
650695.0,"Jefferies Downgrades ICON To Hold, Cites Lower Bookings, Sales",2016-06-03 10:24:00-04:00,ICLR,negative
650696.0,Benzinga's Top Downgrades,2016-06-03 08:59:00-04:00,ICLR,positive
650697.0,Jefferies Downgrades Icon to Hold,2016-06-03 07:03:00-04:00,ICLR,neutral
650698.0,"ICON Q1 EPS $1.12 vs $1.11 est, Revenue $400.5M vs $414.4M est",2016-04-26 06:09:00-04:00,ICLR,neutral
650699.0,"ICON Q4 EPS $1.11 vs $1.10 est, Revenue $403.3M vs $409.2M est",2016-02-23 06:02:00-05:00,ICLR,neutral
650700.0,"ICON Acquires PMG Research, Inc., no terms",2015-12-07 08:34:00-05:00,ICLR,negative
650701.0,"ICON Q3 EPS $1.02 vs $1.01 est, Revenue $395M vs $399M est",2015-10-27 06:00:00-04:00,ICLR,neutral
650702.0,"ICON, IBM Partner On Clinical Trial Feasibility, Patient Recruitment & Study Start-Up Timelines",2015-09-10 08:03:00-04:00,ICLR,neutral
650703.0,"Credit Suisse Assumes Icon at Outperform, Announces $90.00 PT",2015-08-14 04:47:00-04:00,ICLR,positive
650704.0,"KeyBanc Reiterates Overweight on Icon, Raises PT to $85.00",2015-07-29 07:18:00-04:00,ICLR,negative
650705.0,"Icon Q2 EPS $0.95 vs $0.89 est, Revenue $389M vs $402M est, Announces $400M buyback",2015-07-28 06:03:00-04:00,ICLR,neutral
650706.0,Cancer Genetics Inc. Announces a Partnership With ICON's Laboratory Services to Offer Comprehensive Oncology Laboratory Testing and Solutions,2015-07-07 07:00:00-04:00,ICLR,negative
650707.0,Jefferies Boosts Targets Across Pharmaceutical Service Stocks,2015-05-27 11:59:00-04:00,ICLR,positive
650708.0,"Icon Raises FY Guidance to $3.60-$3.70, Previous $3.45-$3.60",2015-04-28 06:16:00-04:00,ICLR,neutral
650709.0,"Icon Q1 EPS $0.86 vs $0.82 est, Revenue $388.2M vs $391.11M est",2015-04-28 06:02:00-04:00,ICLR,neutral
650710.0,ICON Completes Acquisition of MediMedia Pharma Solutions,2015-03-02 06:12:00-05:00,ICLR,positive
650711.0,Icon Q4 EPS $0.87 vs $0.76,2015-02-25 06:01:00-05:00,ICLR,neutral
650712.0,"Earnings Scheduled For February 25, 2015",2015-02-25 04:07:00-05:00,ICLR,neutral
650713.0,ICON to Acquire  MediMedia Pharma Solutions for $120M Cash,2015-02-02 06:02:00-05:00,ICLR,positive
650714.0,Top 4 NASDAQ Stocks In The Medical Laboratories & Research Industry With The Highest EPS,2015-01-29 04:16:00-05:00,ICLR,positive
650715.0,Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Lowest PEG Ratio,2014-12-19 04:10:00-05:00,ICLR,negative
650716.0,ICON Is Now A Strong Buy: Should It Be In Your Portfolio?,2014-12-17 08:14:00-05:00,ICLR,positive
650717.0,ICON Awarded Project by FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials ,2014-11-06 06:37:00-05:00,ICLR,positive
650718.0,ICON plc Raises FY2014 EPS Guidance from $2.62-2.68 to $2.74-2.79 vs $2.66 Est; Narrows FY2014 Sales Guidance from $1.49B-1.53B to $1.50B-1.52B vs $1.51B Est,2014-10-22 06:14:00-04:00,ICLR,neutral
650719.0,ICON plc Reports Q3 EPS of $0.79 vs $0.70 Est; Revenue of $387.60M vs $391.12M Est,2014-10-22 06:06:00-04:00,ICLR,neutral
650720.0,ISI Group Downgrades ICON plc to Neutral,2014-10-10 05:38:00-04:00,ICLR,neutral
650721.0,ICON Plc Announces Further Share Buyback Program for up to $100M,2014-09-19 06:01:00-04:00,ICLR,positive
650722.0,ICON Sees FY2014 EPS $2.62-2.68 vs $2.37 Est; Sees Sales $1.49B-1.53B vs $1.51B Est,2014-07-30 06:28:00-04:00,ICLR,neutral
650723.0,ICON Reports Q2 EPS Ex-items of $0.64 vs $0.58 Est; Revenue of $376.0M vs $376.89M Est,2014-07-30 06:11:00-04:00,ICLR,neutral
650724.0,Top 4 NASDAQ Stocks In The Medical Laboratories & Research Industry With The Highest Profit Margin,2014-05-23 04:43:00-04:00,ICLR,positive
650725.0,DA Davidson Upgrades ICON plc to Outperform,2014-05-01 08:30:00-04:00,ICLR,neutral
650726.0,"ICON plc Down Over 3% Despite Beating on the Bottom Line, Guiding Slightly Higher",2014-04-30 12:43:00-04:00,ICLR,positive
650727.0,Aptiv Solutions to be Acquired by ICON for $143.5M,2014-03-31 09:02:00-04:00,ICLR,positive
650728.0,US Stock Futures Up Ahead Of Chicago PMI,2014-03-31 07:31:00-04:00,ICLR,neutral
650729.0,ICON to Acquire Aptiv Solutions for $143.5M in Cash,2014-03-31 06:04:00-04:00,ICLR,positive
650730.0,UPDATE: Credit Suisse Initiates Coverage on ICON plc as Momentum is Poised to Continue,2014-03-27 08:55:00-04:00,ICLR,positive
650731.0,Benzinga's Top Initiations,2014-03-27 07:59:00-04:00,ICLR,positive
650732.0,"Credit Suisse Initiates Coverage on ICON plc at Outperform, Announces $55.00 PT",2014-03-27 06:54:00-04:00,ICLR,positive
650733.0,ICON Reports Q4 EPS of $0.53 vs $0.45 Est; Revenue of $345.20M vs $339.86M Est,2014-02-20 06:02:00-05:00,ICLR,neutral
650734.0,ICON Names Dr. Steve Cutler as COO,2014-01-09 09:34:00-05:00,ICLR,neutral
650735.0,"Option Alert: Icon January $40 Call; 1,992 Contract Trade at Ask @$1.70; Currently $40.67",2014-01-08 12:06:00-05:00,ICLR,positive
650736.0,UPDATE: ISI Group Upgrades ICON plc Following Weaker PRXL Results,2013-10-31 10:09:00-04:00,ICLR,negative
650737.0,"ISI Group Upgrades ICON plc to Strong Buy, Maintains $49.00 PT",2013-10-31 07:57:00-04:00,ICLR,positive
650738.0,"Raymond James Downgrades ICON plc to Outperform, Raises PT to $48.00",2013-10-25 08:47:00-04:00,ICLR,neutral
650739.0,"UBS Initiates Coverage on ICON plc at Buy, Announces $50.00 PT",2013-09-17 07:23:00-04:00,ICLR,neutral
650740.0,  Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Lowest PEG Ratio,2013-07-30 04:18:00-04:00,ICLR,negative
650741.0,ICON plc Reports Q2 Adjusted EPS of $0.43 vs $0.38 Est; Revenue of $334.20M vs $321.82M Est,2013-07-25 06:25:00-04:00,ICLR,neutral
650742.0,UPDATE: Sterne Agee Resumes ICON at Neutral on Valuation,2013-06-12 10:21:00-04:00,ICLR,neutral
650743.0,"Sterne Agee Initiates Coverage on ICON plc at Neutral, Announces $34.00 PT",2013-06-11 16:16:00-04:00,ICLR,neutral
650744.0,ICON plc Reports Q1 EPS of $0.36 vs $0.34 Est; Revenue of $316.80M vs $302.37M Est,2013-04-25 06:22:00-04:00,ICLR,neutral
650745.0,UPDATE: Jefferies Raises PT to $38 on ICON plc; Strategic Partnerships Paying Off,2013-03-12 14:55:00-04:00,ICLR,neutral
650746.0,"Jefferies Maintains Buy on ICON plc, Raises PT to $38.00",2013-03-12 06:58:00-04:00,ICLR,neutral
650747.0,"UPDATE: ISI Group Reiterates Buy Rating, Raises PT on ICON plc on Solid 4Q Results",2013-02-20 10:41:00-05:00,ICLR,negative
650748.0,"Raymond James Upgrades ICON plc to Strong Buy, Raises PT to $37.00",2013-02-20 09:29:00-05:00,ICLR,positive
650749.0,"ISI Group Maintains Buy on ICON plc, Raises PT to $33.00",2013-02-20 09:06:00-05:00,ICLR,neutral
650750.0,"JP Morgan Maintains Neutral on ICON plc, Raises PT to $28.00",2013-02-19 16:11:00-05:00,ICLR,positive
650751.0,Cross Country Healthcare Completes Sale of Clinical Trial Services Business to ICON,2013-02-19 06:18:00-05:00,ICLR,neutral
650752.0,ICON plc Reports Q4 EPS of $0.34 vs $0.33 Est; Revenue of $300.0M vs $291.96M Est,2013-02-19 06:15:00-05:00,ICLR,neutral
650753.0,Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest Revenue Estimates,2013-02-06 03:08:00-05:00,ICLR,positive
650754.0,ICON Begins Direct Trading on NASDAQ ,2013-02-05 06:06:00-05:00,ICLR,neutral
650755.0,"Jefferies Reiterates Buy Rating, $32 PT on ICON plc on Clinical Trial Staffing Acquisition",2013-02-04 13:17:00-05:00,ICLR,neutral
650756.0,A Peek Into The Market Before The Trading Starts,2013-02-04 07:10:00-05:00,ICLR,neutral
650757.0,ICON to Acquire Clinical Trial Services Division of Cross Country Healthcare for 52M in Cash,2013-02-04 06:04:00-05:00,ICLR,neutral
650758.0,"UPDATE: Sterne Agee Reiterates Neutral Rating, Raises PT on ICON plc",2013-01-14 14:11:00-05:00,ICLR,neutral
650759.0,"Sterne Agee Maintains Neutral on ICON plc, Raises PT to $25.00",2013-01-14 09:40:00-05:00,ICLR,neutral
650760.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on ICON plc",2012-12-05 11:18:00-05:00,ICLR,neutral
650761.0,ICON Shares Higher Despite Raymond James Downgrade to Market Perform,2012-12-05 10:44:00-05:00,ICLR,positive
650762.0,"Jefferies Maintains Buy on ICON plc, Raises PT to $32.00",2012-12-05 06:56:00-05:00,ICLR,neutral
650763.0,"ISI Group Maintains Overweight on ICON plc, Raises PT to $33.50",2012-12-04 14:34:00-05:00,ICLR,negative
650764.0,UPDATE: ICON plc Sees FY2013 EPS $1.40-1.55 vs $1.50 Est; Sees Sales $1.21B-1.24B vs $1.24B Est,2012-12-03 17:52:00-05:00,ICLR,neutral
650765.0,ICON plc Sees FY2013 EPS $1.40-1.55 vs $1.50 Est,2012-12-03 17:51:00-05:00,ICLR,neutral
650766.0,"Four European Stocks Worth a Look Now (DLPH, ICLR, IR, LYB)",2012-11-24 17:02:00-05:00,ICLR,positive
650767.0,"Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)",2012-11-03 10:07:00-04:00,ICLR,positive
650768.0,"Robert W. Baird Upgrades Icon from Neutral to Outperform, Raises PT from $25 to $30",2012-11-02 10:37:00-04:00,ICLR,neutral
650769.0,Icon Reports Q3 EPS $0.41 vs $0.27 Est; Revenues $86.6M,2012-11-01 07:48:00-04:00,ICLR,neutral
650770.0,UPDATE: Jefferies Upgrades ICON to Buy on Management Confidence  ,2012-09-10 08:47:00-04:00,ICLR,positive
650771.0,"Jefferies & Company Upgrades Icon from Hold to Buy, Raises PT from $24 to $29",2012-09-10 06:34:00-04:00,ICLR,neutral
650772.0,Icon Reports Q2 EPS $0.21 vs $0.22 Est; Revenues $277M vs $266.91M Est,2012-07-24 06:32:00-04:00,ICLR,neutral
650773.0,"UPDATE: ISI Group Initiates ICON Plc with Overweight, $26 PT on Scaling and Monetization  ",2012-07-10 09:21:00-04:00,ICLR,negative
650774.0,"ISI Group Initiates Coverage on Icon at Overweight, Announces PT of $36",2012-07-10 06:07:00-04:00,ICLR,negative
650775.0,UPDATE: Jefferies Raises PT to $24 on ICON; Solid Qtr  ,2012-04-25 09:49:00-04:00,ICLR,positive
650776.0,"Jefferies & Company Maintains Icon at Hold, Raises PT from $18.5 to $24",2012-04-25 06:17:00-04:00,ICLR,neutral
650777.0,Icon Reports Q1 EPS $0.15 vs $0.15 Est; Revenues $252.3M vs $256.04M Est,2012-04-24 07:23:00-04:00,ICLR,neutral
650778.0,ICON Acquires PriceSpective ,2012-02-28 06:35:00-05:00,ICLR,neutral
650779.0,UPDATE: Jefferies Raises Target to $18.50 on ICON,2012-02-17 11:12:00-05:00,ICLR,neutral
650780.0,Icon Reports Q4 EPS $0.07 vs $0.09 Est; Revenues $242.6M vs $251.92M Est	 				,2012-02-16 06:48:00-05:00,ICLR,neutral
650781.0,UPDATE: Sterne Agee Upgrades ICON ,2012-02-15 09:07:00-05:00,ICLR,neutral
650782.0,"Sterne Agee Upgrades Icon from Underperform to Neutral, Raises PT to $21",2012-02-15 07:14:00-05:00,ICLR,neutral
650783.0,ICON Selected by Shire as Global Strategic Partner for Clinical Research and Central Laboratory Services  ,2012-01-09 07:21:00-05:00,ICLR,neutral
650784.0,Deutsche Bank Downgrades ICON to Hold,2012-01-03 13:06:00-05:00,ICLR,neutral
650785.0,Market Roundup,2011-12-27 13:47:00-05:00,ICLR,neutral
650786.0,ICON Announces Dr. Anthony Murphy To Retire From Board of Directors   ,2011-12-27 06:46:00-05:00,ICLR,neutral
650787.0,ICON Acquires BeijingWits Medical Consulting Ltd   ,2011-12-12 06:50:00-05:00,ICLR,neutral
650788.0,ICON Acquires BeijingWits Medical Consulting,2011-12-12 06:48:00-05:00,ICLR,neutral
650789.0,Tasly Pharmaceuticals Selects ICON as it Seeks First FDA Approval of a Traditional Chinese Medicine  ,2011-11-22 17:23:00-05:00,ICLR,positive
650790.0,Tasly Pharmaceuticals Selects ICON as it Seeks First FDA Approval of a Traditional Chinese Medicine   ,2011-11-21 06:51:00-05:00,ICLR,positive
650791.0,ICON Reports Q3 EPS $0.02 vs $0.01 Est; Revenues $240.8M vs $239.92M Est				,2011-10-27 07:40:00-04:00,ICLR,neutral
650792.0,Stocks Hitting 52-Week Lows,2011-10-11 12:07:00-04:00,ICLR,negative
650793.0,"UPDATE: JP Morgan Downgrades ICLR To Neutral, Lowers PT to $18",2011-10-10 07:58:00-04:00,ICLR,positive
650794.0,"JP Morgan Downgrades ICON Plc to Neutral, PT Lowered to $18",2011-10-10 06:20:00-04:00,ICLR,positive
650795.0,ICON Announces Peter Gray To Retire As CEO  ,2011-09-07 06:59:00-04:00,ICLR,neutral
650796.0,A Peek Into The Market Before The Trading Starts,2011-08-30 07:31:00-04:00,ICLR,neutral
650797.0,ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb  ,2011-08-30 06:49:00-04:00,ICLR,neutral
650798.0,Jefferies Downgrades ICON plc to Hold from Buy and Lowers PT from $28 to $21.50,2011-07-21 07:47:00-04:00,ICLR,negative
650799.0,"Jefferies Downgrades ICLR, PRXL",2011-07-21 06:32:00-04:00,ICLR,neutral
650800.0,Market Roundup,2011-07-14 10:50:00-04:00,ICLR,neutral
650801.0,ICON Acquires Firecrest Clinical; Terms not Disclosed,2011-07-14 07:55:00-04:00,ICLR,neutral
650802.0,ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development   ,2011-05-26 08:35:00-04:00,ICLR,neutral
650803.0,"Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest EPS Estimates (ICLR, PRXL, BRLI, MTOX)",2011-04-20 00:14:00-04:00,ICLR,positive
650804.0,"Deutsche Bank Maintains Buy Rating On CVD, ICLR",2011-04-14 08:10:00-04:00,ICLR,neutral
650805.0,Deutsche Bank Reiterates Buy Rating On CVD And ICLR,2011-04-05 08:03:00-04:00,ICLR,neutral
650806.0,"Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest Revenue (PRXL, ICLR, AIQ, BRLI)",2011-03-15 03:03:00-04:00,ICLR,positive
650807.0,"Mad Money Lightning Round OT: Cramer Thinks That TRGL Should Be Bought (ICLR, ERTS, TRGL)",2011-02-08 19:47:00-05:00,ICLR,negative
650808.0,Jefferies Prime Time AM Tickers,2011-01-25 10:53:00-05:00,ICLR,neutral
650809.0,MDU RESOURCES (MDU) - Profit Tracks,2010-12-14 07:33:00-05:00,ICLR,positive
650810.0,MDU RESOURCES (MDU) - Profit Tracks,2010-12-14 00:00:00-05:00,ICLR,positive
650811.0,"Mad Money Lightning Round: Cramer Likes Honeywell (HON, JAZZ, ICLR, ANDE, DE, TSCO, STD, FCS, BIDU, GOOG, NAT)",2010-11-09 03:36:00-05:00,ICLR,negative
650812.0,Standpoint Initiates Buy Rating on ICON (ICLR),2010-10-25 12:04:00-04:00,ICLR,neutral
650813.0,"Three Stocks Seeing Record Volume (FNF, PLCE, ICLR)",2010-10-21 13:08:00-04:00,ICLR,neutral
650814.0,"Benzinga's Volume Movers (ICLR, TZOO, ALXN, MAT)",2010-10-21 11:40:00-04:00,ICLR,neutral
650815.0,ICON Downgraded to Neutral,2010-10-05 09:46:00-04:00,ICLR,neutral
650816.0,Deutsche Bank: ICLR And CVD Continue To Be Best Secular Growth Stories In CRO Space,2010-07-13 10:44:00-04:00,ICLR,positive
650817.0,"ICON Receives ‘Buy’ Rating (GS, ICLR, PPDI)",2010-06-16 16:24:00-04:00,ICLR,neutral
650818.0,Top PIIGS Stocks,2010-03-03 02:05:00-05:00,ICLR,positive
650819.0,ICON (ICLR) Maintains A Buy Rating,2010-02-26 20:58:00-05:00,ICLR,neutral
650820.0,"Benzinga’s Volume Movers (VLTR, AMLN, PRXL, ICLR, ZION)",2010-01-26 14:10:00-05:00,ICLR,neutral
